This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Catabasis Pharmaceuticals Inc. (developing therapies for inflammatory, immunological, and metabolic diseases) brought in $32.4mm via a Series B financing to first-time backer Lightstone Ventures, which was joined by an undisclosed public crossover fund and all existing shareholders Advanced Technology Ventures, Clarus Ventures, MedImmune Ventures, and SV Life Sciences. Catabasis says the money should last into 2015 and help the company prep for Phase III trials of its triglyceride-lowering candidate CAT2003 and support ongoing development of other candidates based on its SMART linker conjugate technology.
Already a Strategic Transactions subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?